secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016267
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics Q1 2023 net loss $0.51/sh; cash $21.7M, runway into Q2 2024
--------------------------------------------------------------------------------

- R&D expenses $1.9M (+$0.6M YoY); G&A $2.6M (+$0.5M YoY); net loss per share $0.51 vs $0.41.
- Cash and equivalents $21.7M at March 31, 2023, down from $26.4M at Dec 31, 2022; cash runway into Q2 2024.
- First patient dosed in Phase 1 trial of Decoy20 for solid tumors in March 2023; three trial sites activated.
- Patent allowances in Brazil and India bring IP protection to 32 countries for Decoy platform.
- Robert Martell, M.D., Ph.D. elected to Board of Directors in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/0001493152-23-016267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer